Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04201262 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT04201262 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT04201262, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
Interventions
- BIOLOGICAL Ravulizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04201262
The ClinicalTrials.gov registry entry for NCT04201262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ravulizumab is the first listed.
NCT04201262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04201262 about?
NCT04201262 is a clinical study titled "An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD". The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
What is the current status of trial NCT04201262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2019-12-09. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04201262?
The interventions under investigation include: Ravulizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04201262?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.